- |||||||||| letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. (Pubmed Central) - Apr 23, 2024 To the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane.
- |||||||||| tamoxifen / Generic mfg.
Impact of Anti-estrogen Therapy on the Vaginal Microflora in Breast Cancer Patients () - Apr 20, 2024 - Abstract #ASBrS2024ASBrS_389; While previous studies have associated anti-estrogen therapies with atrophic vaginitis, comparison of the rate of BV amongst women taking and not taking these medications is novel. Further studies should evaluate the incidence of BV and vaginal microbiome composition in women taking anti-estrogen therapies stratified by breast cancer course and surgical treatment to better understand the relationship and identify potential therapeutic avenues for improved quality of life.
- |||||||||| tamoxifen / Generic mfg.
Journal, Adherence: Follow-up Routines Matter for Adherence to Endocrine Therapy in the Adjuvant Setting of Breast Cancer. (Pubmed Central) - Apr 17, 2024 Medication persistence for 4 years and more was good and similar between patients initiating aromatase inhibitor (AI) and tamoxifen (75.7% and 72.0%, respectively, P = .43)...Adherence to ET in BC is high in Western Sweden. Less regular nurse-initiated contacts between BC patients and nursesled surprisingly to a better adherence than a more regular nurse-initiated contact.
- |||||||||| duloxetine / Generic mfg.
Review, Journal: Current and future advances in practice: aromatase inhibitor-induced arthralgia. (Pubmed Central) - Apr 11, 2024 There was consistent improvement in AIAs with switching to an alternate AI, and this could additionally allow continuation of cancer treatment with AI. Further research is needed to identify predictive biomarkers, better characterize AIA subcategories and study more reliable therapeutic options.
- |||||||||| Truqap (capivasertib) / Otsuka, AstraZeneca
Review, Journal, Metastases: Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer. (Pubmed Central) - Apr 3, 2024 Capivasertib is a viable treatment option for patients with PIK3CA/AKT1/PTEN activating mutations following progression on endocrine-based regimens in the metastatic setting or recurrence within 12 months of completing adjuvant therapy. Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Review, Journal, Metastases: CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. (Pubmed Central) - Apr 1, 2024 When combined with an aromatase inhibitor or fulvestrant, these agents have been approved as first-line therapy in the metastatic setting...This manuscript aims to review CDK4/6 inhibitor-related treatment-associated adverse events, identify risk factors for intolerable adverse events, and assess their safety in special patient populations such as the elderly and those with renal insufficiency. Enhanced knowledge and understanding of CDK4/6 inhibitor-related toxicities can improve treatment strategies and ultimately enhance patient care.
- |||||||||| Journal: Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling. (Pubmed Central) - Mar 27, 2024
Additionally, protein expression and phosphorylation patterns, while under different regulation, still recapitulated the estrogen-independent phenotype of ER mutant cells. Our study is the first proteome-centric characterization of ESR1 mutant models, out of which we confirm estrogen independence of ER mutants and reveal the enrichment of immune signaling pathways at the proteomic level.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Neonatal aromatase inhibition blocked defeminization of AVPV Kiss1 neurons and LH surge-generating system in male rats. (Pubmed Central) - Mar 27, 2024 The results of the present study showed that the neonatal administration of letrozole (LET), a nonsteroidal aromatase inhibitor, within 2?hours of birth rescued AVPV Kiss1 expression and the LH surge in adult male rats, while the neonatal administration of testosterone propionate (TP) irreversibly attenuated AVPV Kiss1 expression and the LH surge in adult female rats...Moreover, neonatal TP administration significantly decreased the number of arcuate (ARC) Kiss1-expressing and Kiss1-Cre-activated tdTomato-positive cells and suppressed LH pulses in adult gonadectomized female rats; however, neonatal LET administration failed to affect them. These results suggest that E2 converted from neonatal testosterone is primarily responsible for the defeminization of AVPV kisspeptin neurons and the subsequent GnRH/LH surge generation in male rats.
- |||||||||| Retrospective data, Journal: A computed tomography radiomics-based model for predicting osteoporosis after breast cancer treatment. (Pubmed Central) - Mar 26, 2024
The predictive model combining clinical and radiomic features showed the greatest adjusted R value (0.557), sensitivity (83.6%), specificity (74.2%) and total accuracy (79.4%) compared to models that relied solely on clinical data, radiomic features, or Hounsfield units. In conclusion, the clinical-radiomic predictive model may be used as an opportunistic screening tool for early identification of breast cancer survivors at high risk of CTIBL based on non-contrast CT images of the L1 vertebra, thereby facilitating early intervention for osteoporosis.
- |||||||||| tranexamic acid oral / Generic mfg.
Review, Journal: The efficacy of medical management of leiomyoma-associated heavy menstrual bleeding: a mini review. (Pubmed Central) - Mar 25, 2024 Medical management of HMB is the preferred first-line treatment and includes nonsteroidal anti-inflammatory drugs, contraceptive hormones, tranexamic acid, levonorgestrel intrauterine system, gonadotropin-releasing hormone (GnRH) antagonists and antagonists, selective progesterone receptor modulators, selective estrogen receptor modulators, and aromatase inhibitors...Patients may also face financial barriers to GnRH analog therapy. Future studies are required to delineate the nonhormonal treatment options and the long-term management of leiomyoma-associated HMB.
- |||||||||| Preclinical, Journal: Evaluating flavonoids as potential aromatase inhibitors for breast cancer treatment: In vitro studies and in silico predictions. (Pubmed Central) - Mar 25, 2024
Flavonoids with IC50 values less than 10 ?M, pinocembrin, eriodictyol, naringenin, liquirtigenin, sakuranetin, and chrysin, exhibited favorable physicochemical properties and ADME profiles, suggesting their potential for development as novel flavonoid-based aromatase inhibitors. This study would provide valuable insights for the development of flavonoid-based aromatase inhibitors for the treatment of breast cancer.
|